Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|
| 10% | | 22.97M | $519.13M | - |
| CEO | | 257.3K | $5.81M | -84,767 |
| COO | | 139.0K | $3.14M | -6,120 |
| Other | | 58.1K | $1.31M | -29,670 |
| VP | | 36.0K | $814.0K | -19,848 |
| ? | | 23.0K | $519.8K | - |
| ? | | 11.5K | $259.9K | - |
| ? | | 11.5K | $259.9K | - |
| ? | | 11.5K | $259.9K | - |
| ? | | 11.5K | $259.9K | - |
| ? | | 11.5K | $259.9K | - |
| ? | | 11.5K | $259.9K | - |
| VP | | 459 | $10.4K | - |
Transactions
50 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|
| 2026-01-12 | Hollywood Mark | EVP & Chief Operating Officer | Sale+OE | 6,120 | $22.67 | $138,761.82 | -4.4% | → |
| 2026-01-12 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sale+OE | 9,310 | $22.67 | $211,090.29 | -25.8% | → |
| 2026-01-12 | Galbraith Kenneth | Chair & CEO | Sale+OE | 30,424 | $22.67 | $689,818.56 | -11.8% | → |
| 2026-01-12 | Moore Paul Andrew | Chief Scientific Officer | Sale+OE | 9,560 | $22.67 | $216,758.66 | -16.5% | → |
| 2026-01-05 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sale+OE | 10,538 | $25.10 | $264,471.13 | -36.5% | → |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Sale+OE | 54,343 | $25.10 | $1,363,840.84 | -13.4% | → |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Sale+OE | 20,110 | $25.10 | $504,698.66 | -21.9% | → |
| 2025-12-22 | Galbraith Kenneth | Chair & CEO | Sale+OE | 47,528 | $27.02 | $1,284,311.12 | -26.3% | → |
| 2025-05-19 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 55,421 | $11.47 | $635,585.71 | +0.2% | → |
| 2025-04-17 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 128,713 | $11.32 | $1,456,407.88 | +0.4% | → |
| 2025-04-04 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 317,208 | $11.42 | $3,623,970.36 | +0.9% | → |
| 2025-04-02 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 127,415 | $11.75 | $1,497,322.33 | +0.2% | → |
| 2025-03-26 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 97,349 | $12.61 | $1,227,309.18 | +0.3% | → |
| 2025-03-24 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 127,198 | $12.92 | $1,643,247.98 | +0.2% | → |
| 2025-03-19 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 228,463 | $12.55 | $2,866,552.72 | +0.5% | → |
| 2025-03-13 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 1,081,980 | $12.13 | $13,120,914.17 | +2.2% | → |
| 2025-01-17 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 141,429 | $13.88 | $1,963,538.26 | +0.5% | → |
| 2025-01-15 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 167,654 | $13.59 | $2,278,811.37 | +0.4% | → |
| 2025-01-10 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 225,119 | $13.21 | $2,974,818.88 | +0.7% | → |
| 2025-01-06 | Moore Paul Andrew | Chief Scientific Officer | Sale+OE | 21,200 | $14.92 | $316,390.92 | -35.8% | → |
| 2025-01-06 | Galbraith Kenneth | Chair & CEO | Sale+OE | 57,291 | $14.92 | $855,016.61 | -30.9% | → |
| 2025-01-06 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sale+OE | 11,110 | $14.92 | $165,806.75 | -55.5% | → |
| 2025-01-02 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 363,369 | $14.64 | $5,321,175.87 | +0.8% | → |
| 2024-12-27 | EcoR1 Capital, LLC | Director, 10% Owner | Buy | 130,309 | $14.44 | $1,882,114.86 | +0.3% | → |
| 2024-01-08 | Galbraith Kenneth | Chair & CEO | Sale+OE | 5,706 | $11.22 | $63,996.21 | -19.4% | → |
| 2024-01-08 | Astle Christopher | SVP & Chief Financial Officer | Sale+OE | 1,431 | $11.22 | $16,049.52 | -18.0% | → |